Nektar Therapeutics (NKTR) PT Raised to $63 at Evercore ISI; 'Highlights from 4Q earnings call'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Nektar Therapeutics (NKTR) PT Raised to $94 at Canaccord Genuity
March 2, 2018 7:24 AM ESTCanaccord Genuity raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $94.00 (from $80.00) while maintaining a Buy rating.
... MoreMizuho Sees Potential Nektar Therapeutics (NKTR) Takeover by Bristol-Myers Squibb (BMY) This Year
March 2, 2018 6:31 AM ESTMizuho Securities analyst Difei Yang believes there is a possibility of a Nektar Therapeutics (NASDAQ: NKTR) take-out in 2018 and new positive clinical data of NKTR-214 in combo with Bristol-Myers Squibb (NYSE: BMY) Opdivo reinforces their... More
Nektar Therapeutics (NKTR) PT Raised to $103 at Jefferies
March 2, 2018 1:01 AM ESTJefferies raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $103.00 (from $88.00) while maintaining a Buy rating.
... More